Ipsen has announced the start of a Phase II clinical trial to evaluate the safety and efficacy of BN83495, an investigational first-in-class steroid sulfatase (STS) inhibitor to treat advanced endometrial cancer.
The novel treatment, BN83495, will be trialled in an attempt to establish progression-free survival in post-menopausal women with histologically confirmed hormone receptor positive endometrial cancer who are not eligible for treatment with surgery and radiotherapy.
Ipsen executive vice-president Stéphane Thiroloix said that this first-in-class steroid sulfatase inhibitor can potentially significantly improve lives of patients with advanced endometrial cancer.
"With further indications in breast, prostate and ovarian cancers, we believe Ipsen with its focus on hormone dependent cancers will fully leverage the value of BN83495," he said.
BN83495 is a first-in-class orally available irreversible steroid sulfatase (STS) inhibitor, which prevents the growth of hormone-dependent tumours.